ReviewEmerging microbes & infections2022
Carbapenemase-producing
Review in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
147 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.Antimicrobial agents and chemotherapy · 2024Trial
- Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA.The Lancet. Infectious diseases · 2026Review
- Glutamate Potentiates Meropenem Killing of Carbapenem-ResistantACS omega · 2026Article
- Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- Natural occurrence of a slow lytic pseudomonas phage in a Pediatric case of multidrug-resistant P. aeruginosa severe pneumonia.Virus genes · 2026Article
- Metallo-beta-lactamase α-helix fragment modified peptide N10 is a multifunctional antimicrobial peptide.Microbiology spectrum · 2026Article
- Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa.Infection · 2026Review
- Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Changes in the Epidemiology of Multidrug-Resistant Organisms During the COVID-19 Pandemic: A Six-Year Retrospective Study at a Tertiary Care Hospital in Northeastern Thailand.Medical sciences (Basel, Switzerland) · 2026Observational
- Comparative genome analysis of carbapenemase-producing Pseudomonas aeruginosa: gene diversity, clonal distribution, and genome dynamics.Molecular genetics and genomics : MGG · 2026Article
- Recalibration and Validation of a Risk Scoring Tool to Predict Multidrug-ResistantOpen forum infectious diseases · 2026Article
- Molecular evolution and mechanisms underlying extremely high-level carbapenem resistance in the emerging CRPA clone ST1976.BMC microbiology · 2026Article
- Multicenter Genomic Analysis of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Emergence of KPC-producingAntimicrobial agents and chemotherapy · 2026Article
- Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica.The Journal of antimicrobial chemotherapy · 2026Article
- Genomic characterization of the multidrug-resistant IncP-2 plasmid pPAMS in a clinical isolate Pseudomonas aeruginosa.BMC microbiology · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Review
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.